Literature DB >> 12034572

Polymers of alpha(1)-antitrypsin are chemotactic for human neutrophils: a new paradigm for the pathogenesis of emphysema.

Jasvir S Parmar1, Ravi Mahadeva, Benjamin J Reed, Neda Farahi, Karen A Cadwallader, Mary T Keogan, Diana Bilton, Edwin R Chilvers, David A Lomas.   

Abstract

Plasma deficiency of alpha(1)-antitrypsin is most commonly due to the Z mutation ((342)Glu--> Lys) and is associated with early-onset panlobular emphysema. The lung disease in these patients is attributed to the relative deficiency of circulating alpha(1)-antitrypsin resulting in uncontrolled neutrophil-derived proteolytic activity. We have previously demonstrated that the local deficiency of Z alpha(1)-antitrypsin is exacerbated by the formation of polymers within the lung and now show that this polymerization not only inactivates alpha(1)-antitrypsin but also converts the molecule to a chemoattractant for human neutrophils. The chemotactic action of polymeric alpha(1)-antitrypsin was substantially greater than that seen with other conformers, was of similar magnitude to C5a, and was apparent over a range of physiologically relevant concentrations (EC(50) 0.0045 +/- 0.002 mg/ml). The biologic activity of polymeric alpha(1)-antitrypsin was confirmed by the demonstration that polymers, but not native alpha(1)-antitrypsin, induced neutrophil shape change and stimulated myeloperoxidase release and neutrophil adhesion. Polymeric alpha(1)-antitrypsin had no effect on basal or N-formyl-Met-Leu-Phe- stimulated superoxide anion release or constitutive apoptosis. The chemotactic properties of polymeric alpha(1)-antitrypsin may provide an explanation for the excessive neutrophils found in the lungs of Z alpha(1)-antitrypsin homozygotes and suggests a new paradigm for the pathogenesis of emphysema in these patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12034572     DOI: 10.1165/ajrcmb.26.6.4739

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  36 in total

Review 1.  Alpha1-antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy.

Authors:  David A Lomas; Ravi Mahadeva
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

2.  Molecular multitasking in the airspace: alpha1-antitrypsin takes on thrombin and plasmin.

Authors:  Rubin M Tuder; Irina Petrache
Journal:  Am J Respir Cell Mol Biol       Date:  2007-05-31       Impact factor: 6.914

Review 3.  Protein misfolding and the serpinopathies.

Authors:  Didier Belorgey; Peter Hägglöf; Susanna Karlsson-Li; David A Lomas
Journal:  Prion       Date:  2007-01-06       Impact factor: 3.931

Review 4.  Alpha-1 Antitrypsin Deficiency and Accelerated Aging: A New Model for an Old Disease?

Authors:  Diana Crossley; Robert Stockley; Elizabeth Sapey
Journal:  Drugs Aging       Date:  2019-09       Impact factor: 3.923

5.  Expression and secretion of alpha1-proteinase inhibitor are regulated by proinflammatory cytokines in human pancreatic islet cells.

Authors:  Domenico Bosco; Paolo Meda; Philippe Morel; David Matthey-Doret; Dorothée Caille; Christian Toso; Leo H Bühler; Thierry Berney
Journal:  Diabetologia       Date:  2005-07-07       Impact factor: 10.122

6.  Neutrophilic inflammation and IL-8 levels in induced sputum of alpha-1-antitrypsin PiMZ subjects.

Authors:  M Malerba; F Ricciardolo; A Radaeli; C Torregiani; L Ceriani; E Mori; M Bontempelli; C Tantucci; V Grassi
Journal:  Thorax       Date:  2005-11-11       Impact factor: 9.139

7.  New Findings in PiZZ alpha1-antitrypsin deficiency-related panniculitis. Demonstration of skin polymers and high dosing requirements of intravenous augmentation therapy.

Authors:  B Gross; M Grebe; M Wencker; J K Stoller; L M Bjursten; S Janciauskiene
Journal:  Dermatology       Date:  2009-02-16       Impact factor: 5.366

8.  Immunomodulation by alpha(1)-proteinase inhibitor: lack of chemotactic effects of recombinant human alpha(1)-proteinase inhibitor from yeast on human peripheral blood granulocytes.

Authors:  Birgit Mosheimer; Reinhard Alzner; Christian J Wiedermann
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2007-12-03       Impact factor: 4.291

Review 9.  alpha1-Antitrypsin deficiency . 6: new and emerging treatments for alpha1-antitrypsin deficiency.

Authors:  R A Sandhaus
Journal:  Thorax       Date:  2004-10       Impact factor: 9.139

Review 10.  Alpha1-antitrypsin deficiency. 4: Molecular pathophysiology.

Authors:  D A Lomas; H Parfrey
Journal:  Thorax       Date:  2004-06       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.